Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in BRAF-Mutated Solid Tumors
NCT00888134Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in solid tumor, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 4 years. Started Jul 2009; status: completed.
02
Drugs
selumetinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT00888134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888134.